For Admin

  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2012〜
  • CONTACT

Shin Nippon Biomedical Laboratories, Ltd. Translational Research Business

Japanese

A Leading Company in Nasal Drug Delivery

  • HOME
  • BUSINESS
  • TECHNOLOGY
    • Platform Technology
    • Special Analysis
    • Publication
  • APPLICATION
    • Absorption
    • Vaccination
    • Nose-to-Brain
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY

Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Widely Applicable Technology

For Absorption
For Vaccination
For Nose-to-Brain

Expertise in Nasal Delivery

3D Nasal Cast Model

preview
next

News

2025

May 1, 2025

Satsuma Pharmaceuticals Announces U.S. FDA Approval for Atzumi™ (Dihydroergotamine) Nasal Powder for the Acute Treatment of Migraine 

Mar 24, 2025

SNBL’s Subsidiary, SNLD, Announces its Abstract Accepted at the Upcoming 77th American Academy of Neurology (AAN) 2025 Annual Meeting

2025|2024|2023|2022|2021|2020〜

BACK
  • HOME
  • BUSINESS
  • TECHNOLOGY
  • APPLICATION
  • PARTNERING
  • NEWS
  • CONTACT
  • PRIVACY POLICY
Cookie Policy | Sitemap
© Shin Nippon Biomedical Laboratories, Ltd. All Rights Reserved.
Log out | Edit